Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
123
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypereosinophilic Syndrome
Interventions
DRUG:
Depemokimab
OTHER:
Placebo
Sponsor
GlaxoSmithKline